Loading
A phase 2 trial of Nogapendekin alfa inbakicept, Aldoxorubicin, Gemcitabine and Cyclophosphamide in pancreatic ductal adenocarcinoma, run by ImmunityBio, Inc., active and no longer recruiting.
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT04390399 by ImmunityBio, Inc., with 328 participants enrolled, started 2020-07-21 and due to reach its primary completion in 2025-10-13. Interventions recorded: N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine and Cyclophosphamide.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.